APOE Genotype Testing
Last reviewed 25 August 2026 · Evidence-graded review — see Methodology
Genotyping the APOE gene, which has three common alleles (ε2, ε3, ε4). Carrying one or two copies of ε4 substantially raises lifetime risk of late-onset Alzheimer’s disease, and ε4 remains the strongest and most replicated common genetic risk factor for it. The difficulty is not the strength of that association. It is what an asymptomatic person is supposed to do with the result.
Mayeux R, Saunders AM, Shea S, et al. “Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer’s Disease.” N Engl J Med 1998;338:506–511 established APOE’s value alongside clinical assessment in symptomatic patients, where combining clinical diagnosis with genotype improved diagnostic accuracy (AUC 0.87) over clinical diagnosis alone (AUC 0.84). Predictive screening in an asymptomatic person is a different question. Since 2023–2024 APOE testing has acquired one specific new role: it is recommended before starting anti-amyloid therapies such as lecanemab for early Alzheimer’s disease, because ε4 carriers have both a different treatment-response profile and a higher risk of ARIA. Outside that pre-treatment context, or genetic counselling for a strong family history, no preventive intervention has been shown to change an asymptomatic ε4 carrier’s trajectory — and disclosure carries real, studied psychological and insurance or employment-related consequences.
Mayeux R, et al. N Engl J Med. 1998. PubMed: PMID 9468467
Singapore guidance
Not covered in the current review
Singapore’s national screening committee has not reviewed this test in the current volume of its report, which covers nine conditions. That is not a verdict either way.
Source: Screening Test Review Committee report 2026, Volume 1 (Academy of Medicine Singapore and Ministry of Health, February 2026). The full national list · How this is used.
What you would actually pay
- Healthier SG
- Not subsidised
- MediSave
- Not among the screenings named for outpatient claims
Source: Healthier SG Screening (HealthHub) and MediSave outpatient care (Ministry of Health). Absence from either list is not a statement that the test is discouraged — only that no subsidy or claim applies. Gross prices compared.
What it costs when it is wrong
- Basis
- No published harm criterion found
- Severity
- Not documented
Not covered in the current volume of the committee’s report, so no harm criterion was found either way.
An empty finding, not a clean bill of health: this means nothing documented was found for this test. It is not a claim that the test is safe.
Screening harm is not only a laboratory question: the committee’s own criteria advise against a test when “the screening test, or follow-up tests arising from a positive screen, are associated with significant medical risks”. Sources on overdiagnosis → · How this is graded.
FAQ
Is the APOE Genotype Testing worth doing in Singapore?
The evidence behind APOE Genotype Testing is graded weak (for general screening) for screening an asymptomatic adult. It typically costs S$200–400 in Singapore. It is not a screening test — one-off, only within the contexts above, ideally with genetic counselling. It is most appropriate for pre-anti-amyloid-therapy work-up in symptomatic patients, or genetic counselling for strong family history — not general population screening.
Weighing this against something else? Compare it with two other tests → · Price it inside a panel →